The transparency lists set the national reference price for reimbursable off‑patent medicines and are used by regions and autonomous provinces to apply the reference pricing rules laid down in article 9, paragraph 5 of Law 8 August 2002 n. 178. In line with the AIFA Director‑General Determination 166/2021, the new update incorporates all mandatory price measures currently in force, including legal reductions and other AIFA decisions that affect ex‑factory and retail prices.
The communication confirms that the updated lists include the groups of equivalent medicines and their corresponding reference prices, calculated after applying the 5% mandatory reduction that has been reinstated from 1 January 2026, together with any further cuts required by recent legislation and court rulings. The lists are made available in dedicated files on AIFA’s transparency‑list portal and in the historical archive for 2026, with the 15 January 2026 package clearly identified.
AIFA frames the 54th update as part of its regular monthly cycle, aimed at ensuring uniform implementation of national rules on reference pricing across all regions and autonomous provinces. The agency underlines that prescribers, pharmacists and regional authorities must use the latest lists when applying reference prices and any related patient co‑payment rules.
For companies active on the Italian off‑patent market, the January 2026 update locks in a new set of reference benchmarks that reflect both the restored 5% price cut and recent generic competition, increasing pressure on list‑price positioning and on the viability of higher‑priced branded equivalents within each group.
Source: Agenzia italiana del farmaco
Link: AIFA aggiorna le Liste di Trasparenza n. 54 (AIFA updates Transparency Lists no. 54)
Date: 14 January 2026
